http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Aug 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Blue+Owl+Capital+Holdings+LP/26913473.html si-local-file:///var/storage/secattach/20260812/26913473.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Blue+Owl+Capital+Holdings+LP/26913473.html Wed, 12 Aug 2026 16:31:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Blue+Owl+Capital+Holdings+LP/26913473.html si-local-file:///var/storage/secattach/20260812/26913473.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Blue+Owl+Capital+Holdings+LP/26913473.html Wed, 12 Aug 2026 16:31:00 -0400 CNTX O.52485603 http://www.streetinsider.com/Earnings/Context+Therapeutics+Inc.+%28CNTX%29+Misses+Q2+EPS+by+6c/26876873.html <p>Context Therapeutics Inc. (NASDAQ: CNTX) reported Q2 EPS of ($0.15), $0.06 worse than the analyst estimate of ($0.09).</p><p>For earnings history and earnings-related data on Context Therapeutics Inc. (CNTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=CNTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Context+Therapeutics+Inc.+%28CNTX%29+Misses+Q2+EPS+by+6c/26876873.html Thu, 06 Aug 2026 02:45:32 -0400 CNTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Aug+05/26874627.html si-local-file:///var/storage/secattach/20260805/26874627.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Aug+05/26874627.html Wed, 05 Aug 2026 16:17:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Aug+05/26874627.html si-local-file:///var/storage/secattach/20260805/26874627.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Aug+05/26874627.html Wed, 05 Aug 2026 16:17:00 -0400 CNTX O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html <p align="center"><em>Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027</em></p> <p align="center"><em>Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027</em></p> <p>PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights.</p> <p>“During the second quarter, we advanced our http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Reports+Second+Quarter+2026+Operating+and+Pipeline+Progress/26874266.html Wed, 05 Aug 2026 16:14:00 -0400 A.06822034 CNTX O.20026344 O.52485603 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Context+Therapeutics++++++For%3A+Jun+30/26874256.html si-local-file:///var/storage/secattach/20260805/26874256.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Context+Therapeutics++++++For%3A+Jun+30/26874256.html Wed, 05 Aug 2026 16:10:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Context+Therapeutics++++++For%3A+Jun+30/26874256.html si-local-file:///var/storage/secattach/20260805/26874256.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Context+Therapeutics++++++For%3A+Jun+30/26874256.html Wed, 05 Aug 2026 16:10:00 -0400 CNTX O.52485603 http://www.streetinsider.com/Corporate+News/Context+Therapeutics+gets+Nasdaq+minimum+bid+price+deficiency+notice/26850838.html <p>Context Therapeutics Inc. (NASDAQ: CNTX) received a written notice from the Nasdaq Listing Qualifications Department on July 29, 2026, stating the company is not in compliance with Nasdaq Listing Rule 5550(a)(2), known as the Minimum Bid Price Rule.</p><p>The notice was issued because the company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the company's common stock.</p><p>Under Nasdaq Listing Rule 5810(c)(3)(A), Context Therapeutics has an initial 180-calendar-day period, until January 25, 2027, to regain compliance. Compliance can be http://www.streetinsider.com/Corporate+News/Context+Therapeutics+gets+Nasdaq+minimum+bid+price+deficiency+notice/26850838.html Fri, 31 Jul 2026 16:11:38 -0400 CNTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Jul+29/26850800.html si-local-file:///var/storage/secattach/20260731/26850800.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Jul+29/26850800.html Fri, 31 Jul 2026 16:09:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Jul+29/26850800.html si-local-file:///var/storage/secattach/20260731/26850800.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Context+Therapeutics++++++For%3A+Jul+29/26850800.html Fri, 31 Jul 2026 16:09:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Octagon+Capital+Advisors+LP/26850524.html si-local-file:///var/storage/secattach/20260731/26850524.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Octagon+Capital+Advisors+LP/26850524.html Fri, 31 Jul 2026 16:01:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Octagon+Capital+Advisors+LP/26850524.html si-local-file:///var/storage/secattach/20260731/26850524.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Context+Therapeutics+++++++++++++++++++Filed+by%3A+Octagon+Capital+Advisors+LP/26850524.html Fri, 31 Jul 2026 16:01:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Context+Therapeutics+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819993.html si-local-file:///var/storage/secattach/20260727/26819993.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Context+Therapeutics+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819993.html Mon, 27 Jul 2026 16:27:00 -0400 CNTX O.52485603 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Context+Therapeutics+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819993.html si-local-file:///var/storage/secattach/20260727/26819993.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Context+Therapeutics+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819993.html Mon, 27 Jul 2026 16:27:00 -0400 CNTX O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Announces+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26757348.html <p>PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.</p> <p>The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The stock options were granted to a new employee on their hire date http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Announces+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26757348.html Fri, 10 Jul 2026 16:05:00 -0400 CNTX CNTX http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Announces+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26757348.html <p>PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.</p> <p>The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The stock options were granted to a new employee on their hire date http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Announces+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26757348.html Fri, 10 Jul 2026 16:05:00 -0400 CNTX CNTX http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Announces+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26757348.html <p>PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.</p> <p>The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The stock options were granted to a new employee on their hire date http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Announces+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26757348.html Fri, 10 Jul 2026 16:05:00 -0400 CNTX CNTX